Pharmaceutical composition containing cannabinoid-receptor 2 antagonists

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes pharmaceutical compositions that include cannabinoid receptor 2 (CB2R) antagonists, specifically 3-pyrazole-carboxamide derivatives such as SR144528, for preventing or treating cerebral diseases—especially encephalitis—caused by pathogens like parasitic protozoa. The invention covers the use of these antagonists alone or in combination with conventional anti-protozoal drugs (e.g., chloroquine, quinine, artemisinin) to treat severe diseases such as cerebral malaria. The compositions can be formulated for various routes of administration (oral, injectable, topical, or inhalation).

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of cerebral malaria caused by Plasmodium falciparum in humans.
• Prophylaxis or treatment of encephalitis induced by parasitic protozoa (e.g., Toxoplasma, Leishmania, Trypanosoma).
• Treatment of cerebral and neurological complications from other protozoal, bacterial, or viral infections.
• Combination therapy with existing antimalarial or anti-protozoal drugs to improve outcomes in severe infectious diseases affecting the brain.
• Use in both human and veterinary medicine for infections leading to CNS involvement.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers potentially life-saving treatment for cerebral malaria, which has high mortality if untreated.
• Addresses the urgent need for new therapies targeting neurological complications from infectious diseases.
• Combination with existing drugs can enhance effectiveness and possibly reduce resistance or side effects.
• Pharmacological inhibition allows for targeted, controllable therapy, unlike permanent genetic modification (knockouts).
• Multiple administration options (oral, injectable, topical, inhalation), increasing clinical flexibility.
• Potentially broad spectrum, targeting diseases caused by various pathogens including bacteria, viruses, and a range of protozoa.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to the use of cannabinoid-receptor 2 (CB 2 R)-antagonists for the prophylaxis and/or treatment of pathogen, in particular, parasitic protozoa, caused or induced cerebral diseases, disorders or conditions including secondary and accompanying diseases, disorders or conditions, like encephalitis. In a preferred embodiment, said CB 2 R-antagonist is a 3-pyrazole-carboxamide derivative. In a further aspect, the present invention provides pharmaceutical compositions comprising said CB 2 R-antagonist in combination with an anti-pathogenic active ingredient, optionally together with pharmaceutically acceptable carriers, diluents and/or excipients. Said pharmaceutical compositions are useful for treating encephalitis, like cerebral malaria induced by Plasmodium falciparum. Thus, in another aspect, methods for the treatment of pathogen, like parasitic protozoa induced or caused cerebral diseases, disorders or conditions including encephalitis, in particular cerebral malaria are provided comprising the steps of administering a CB 2 R-receptor antagonist.